Article
Oncology
Oladimeji Akinboro, Nicole Drezner, Anup Amatya, Jin Runyan, Jeanne Fourie-Zirkelbach, Miao Zhao, Youwei Bi, Kwadwo Korsah, Bronwyn Mixter, Shenghui Tang, Erin Larkins, Richard Pazdur, Julia A. A. Beaver, Harpreet Singh
Summary: The FDA approved nivolumab plus platinum-doublet chemotherapy for neoadjuvant treatment of resectable NSCLC. The approval was based on the results of a trial showing improved event-free survival with no negative impact on overall survival or surgical outcomes.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Elaine Chang, Chana Weinstock, Lijun Zhang, Mallorie H. Fiero, Miao Zhao, Eias Zahalka, Tiffany K. Ricks, Jeanne Fourie Zirkelbach, Junshan Qiu, Jingyu Yu, Xiao Hong Chen, Vishal Bhatnagar, Kirsten B. Goldberg, Shenghui Tang, Paul G. Kluetz, Richard Pazdur, Amna Ibrahim, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: On March 10, 2021, the FDA approved tivozanib for the treatment of relapsed or refractory kidney cancer patients. The approval was based on the TIVO-3 study, which showed that tivozanib had better efficacy compared to sorafenib and lower rates of adverse reactions.
CLINICAL CANCER RESEARCH
(2022)
Article
Pharmacology & Pharmacy
Hannah A. Blair
Summary: This article provides an overview of the development milestones of Valoctocogene roxaparvovec, a gene therapy for the treatment of hemophilia A, which has recently received conditional marketing authorization in the EU.
Review
Medicine, Research & Experimental
Wentao Li, Lin Liang, Qianjin Liao, Yanling Li, Yanhong Zhou
Summary: This article reviews the expression of CD38 in immune cells and tumor cells, its impact on T cell activity, the relationship between CD38 expression level and disease prediction/prognosis, the effects of anti-CD38 antibodies on T cell activity, and the role of anti-CD38 CAR-T cell therapy in tumor immunity.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Oncology
Hollis Viray, David F. McDermott, David J. Einstein
Summary: Tivozanib is a selective VEGFR inhibitor used in the treatment of RCC. It is considered to be a more potent inhibitor with fewer toxicities. Despite FDA approval, there are still questions about its proper use in the current RCC treatment landscape.
EXPERT REVIEW OF ANTICANCER THERAPY
(2022)
Article
Medicine, General & Internal
Theresa Ermer, Maureen E. Canavan, Richard C. Maduka, Andrew X. Li, Michelle C. Salazar, Michael F. Kaminski, Matthew D. Pichert, Peter L. Zhan, Vincent Mase, Harriet Kluger, Daniel J. Boffa
Summary: This study aimed to assess the association between FDA drug approval and disparities in the use of immunotherapy among cancer patients in the US. The research found that while FDA approval significantly increased the use of immunotherapy, gaps in access persisted, suggesting that FDA approval may not eliminate disparities in the use of novel therapies.
Review
Oncology
Paz J. Vellanki, Flora Mulkey, Adnan A. Jaigirdar, Lisa Rodriguez, Yibo Wang, Yuan Xu, Hong Zhao, Jiang Liu, Grant Howe, Jian Wang, Qiuyi Choo, Sarah J. Golding, Victoria Mansell, Kwadwo Korsah, Dianne Spillman, R. Angelo de Claro, Richard Pazdur, Julia A. Beaver, Harpreet Singh
Summary: On May 26, 2020, FDA approved nivolumab with ipilimumab and two cycles of platinum-doublet chemotherapy as a first-line treatment for metastatic or recurrent non-small cell lung cancer patients, improving overall survival. This approval was based on the results of an open-label trial, demonstrating significant improvements in overall survival, progression-free survival, and overall response rate for patients receiving this combination therapy.
CLINICAL CANCER RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Young-A Heo
Summary: Etranacogene dezaparvovec is a gene therapy based on adeno-associated virus vector, developed by uniQure and CSL Behring for the treatment of hemophilia B. It was approved for the treatment of hemophilia B in the USA in November 2022. In December 2022, it also received positive opinion in the EU.
Article
Multidisciplinary Sciences
Eric J. Mercadante, Jessica L. Tracy, Friedrich M. Goetz
Summary: Social media play a crucial role in modern political campaigning, enabling direct communication between politicians and constituents and facilitating the sharing of political messages. Through analyzing a large dataset of tweets from US senators, a psycholinguistic factor called "greed communication" was found to consistently predict increased approval and reach on social media. This effect remained significant even after accounting for other predictors of political content dissemination and various psycholinguistic variables. Additionally, it was observed that greed communication in tweets from Democratic senators had a stronger association with approval and retweets compared to tweets from Republican senators, especially when mentioning political outgroups.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Review
Immunology
Yuan Song, Yonghao Liu, Huey Yee Teo, Haiyan Liu
Summary: Gamma delta T cells are a type of innate immune cells that can exert cytotoxic functions on target cells without MHC restriction and contribute to adaptive immune response via regulating other immune cells. In the tumor microenvironment, gamma delta T cells can be polarized to different subsets under the influence of cytokines, and their polarization and plasticity provide a basis for gamma delta T cell-based cancer immunotherapy targeting cytokine signals.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Brian E. Harvey
Summary: Nonalcoholic fatty liver disease is a growing public health crisis, with no approved drugs or biological treatments for NASH or related liver diseases. The regulatory pathway for product approval is unclear due to extra-hepatic factors and the organizational structure of FDA.
ACTA PHARMACOLOGICA SINICA
(2022)
Article
Immunology
Martina Musella, Andrea Guarracino, Nicoletta Manduca, Claudia Galassi, Eliana Ruggiero, Alessia Potenza, Ester Maccafeo, Gwenola Manic, Luca Mattiello, Sara Soliman Abdel Rehim, Michele Signore, Marco Pietrosanto, Manuela Helmer-Citterich, Matteo Pallocca, Maurizio Fanciulli, Tiziana Bruno, Francesca De Nicola, Giacomo Corleone, Anna Di Benedetto, Cristiana Ercolani, Edoardo Pescarmona, Laura Pizzuti, Francesco Guidi, Francesca Sperati, Sara Vitale, Daniele Macchia, Massimo Spada, Giovanna Schiavoni, Fabrizio Mattei, Adele De Ninno, Luca Businaro, Valeria Lucarini, Laura Bracci, Eleonora Arico, Giovanna Ziccheddu, Francesco Facchiano, Stefania Rossi, Massimo Sanchez, Alessandra Boe, Mauro Biffoni, Ruggero De Maria, Ilio Vitale, Antonella Sistigu
Summary: The study demonstrates that type I interferons can promote the formation of cancer stem cells by upregulating the chromatin remodeling factor KDM1B. Inhibition of KDM1B could potentially prevent stem cell expansion and increase the long-term benefit of therapy.
Article
Pharmacology & Pharmacy
Yvette N. Lamb
Summary: Imeglimin hydrochloride is an orally administered first-in-class glimin with glucose-lowering effects approved for use in type 2 diabetes in Japan. Its development milestones leading to this approval include positive results from the pivotal phase III TIMES program.
Article
Oncology
M. Nientiedt, K. Mueller, K. Nitschke, P. Erben, A. Steidler, S. Porubsky, Z. V. Popovic, F. Waldbillig, J. Muehlbauer, M. C. Kriegmair
Summary: High B-MYB expression is common in ccRCC patients with high-grade tumors and advanced stages, and is associated with poorer overall survival (OS) and progression-free survival (PFS). These patients show a loss of their physiological B-MYB-p53 network correlation, suggesting an additional, alternative regulatory, oncogenic mechanism. Further characterization of its signaling pathways could potentially make B-MYB a therapy target for ccRCC.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Review
Cell Biology
Shizuo Liu, Shuaijie Yao, Huan Yang, Shuaijie Liu, Yanjiao Wang
Summary: This article discusses the different roles of autophagy in cell death and highlights six main autophagy-related cell death modalities. The article focuses on the metabolic changes caused by excessive ER-phagy-induced cell death and the role of mitophagy in autophagy-mediated ferroptosis. Furthermore, it proposes a new perspective on the clinical treatment of tumors by utilizing autophagy for different functional conversions.
CELL DEATH & DISEASE
(2023)